Personalised HRT: How Glycan Testing Helps Tailor Hormone Therapy for Each Woman

Personalized HRT means calibrating hormone therapy — type, dose, route of administration, and combination — to each woman's individual hormonal and inflammatory biology, rather than applying a standard protocol to all patients. The menopause transition is not a uniform event: estrogen, progesterone, and androgen levels shift at different rates in different women, and the downstream effects on immune function vary accordingly. Hormonal balance matters as much as hormonal levels. Estrogen deficiency and estrogen dominance both drive pro-inflammatory changes in IgG glycosylation (the molecular switches that regulate inflammation), meaning a protocol optimized for one woman may be inadequate or counterproductive for another. Without an objective measure of how a given regimen is affecting systemic inflammation, clinicians are left titrating by symptom alone. This signal lags behind the underlying biology.

Glycan testing closes that gap. By measuring IgG glycosylation (a stable, integrated readout of how the immune system is responding to hormonal change) GlycanAge gives clinicians the objective data needed to assess whether a protocol is working, when to adjust, and how far a patient has actually moved on the biological aging curve.

Read the full clinical framework: Menopause, HRT & Biological Age: The Definitive Guide to Tracking Hormonal Aging.

How does menopause accelerate biological aging at the molecular level?

Menopause accelerates biological aging by shifting IgG glycosylation — the pattern of complex sugars attached to immune antibodies — toward a pro-inflammatory profile. As estrogen declines, anti-inflammatory glycan structures decrease while pro-inflammatory ones, captured in the Glycan Mature (G0) index, increase. This process drives what researchers call inflammaging: the chronic, low-grade inflammation underlying most age-related disease. Women can experience an increase in GlycanAge of over a decade during the menopause transition. A placebo-controlled, randomized trial conducted by GlycanAge confirmed that estrogen depletion is the key driver of this inflammatory shift: suppression of gonadal hormones in healthy premenopausal women produced a marked increase in biological age, while estradiol add-back therapy effectively prevented it. Progesterone, which may decline earlier due to irregular ovulation, exerts distinct anti-inflammatory and neuroprotective effects. Its absence can promote glycan shifts toward inflammation even when estradiol remains intermittently elevated.

What does GlycanAge actually measure, and why is it relevant to HRT?

GlycanAge measures biological age by analyzing IgG glycosylation patterns (the complex sugars attached to the immune antibodies that circulate throughout the body) from a simple finger-prick blood sample. The biological age score is produced by a gender-specific, three-variable multivariate model that combines the glycan structures most strongly associated with aging, reflecting the cumulative balance of pro- and anti-inflammatory glycosylation across the IgG antibody population. This is directly relevant to HRT because IgG glycosylation sits at the interface of hormonal and immune biology: HRT stabilizes glycosylation by counteracting the rise in pro-inflammatory agalactosylated glycans and supporting the maintenance of galactosylated and sialylated structures associated with a youthful immune profile. Galactosylation is captured in the Glycan Youth index, while sialylation is captured in the Glycan Shield index. Both shift measurably in response to well-managed HRT. Because GlycanAge reflects cumulative hormonal and metabolic influence rather than day-to-day hormonal fluctuation, it gives clinicians an integrated view of whether a regimen is working systemically, not just symptomatically.

How much can HRT reduce biological age, and what does the evidence show?

In clinical testing, women on well-managed HRT protocols frequently show biological age reductions of 5 to 25 years. Optimized HRT, calibrated to restore hormonal balance, has been associated with an average GlycanAge improvement of 15 years. This is reflected in the clinical experience at Raffaele Medical, a longevity clinic in New York City where GlycanAge has been incorporated into HRT management for hundreds of patients. Preliminary, unpublished longitudinal data from approximately 40 women receiving HRT, collected in collaboration with Newson Health, show consistent reductions in biological age and pro-inflammatory glycans across three time points. The extent of benefit varies by formulation, dosage, and individual response, and must be interpreted in clinical context.

Can GlycanAge identify when an HRT protocol needs adjustment?

A lack of improvement, or unexpected deterioration, in GlycanAge results is a direct signal that a current HRT regimen is not adequately addressing systemic inflammation, and warrants dose adjustment, formulation change, or broader evaluation of lifestyle and metabolic factors. A clinical case from Raffaele Medical illustrates this precisely: a 55-year-old woman four years post-menopause, already on oral estrogen–progesterone therapy, continued to experience poor sleep, joint aches, and vaginal dryness despite a disciplined lifestyle and good metabolic markers. Her GlycanAge remained elevated above her chronological age. After transitioning to bioidentical estradiol cream with gradual dose adjustments, her GlycanAge decreased by 10 years over 12 months. This shift was not evident from symptoms alone. In clinical practice, optimizing HRT requires careful, ongoing calibration, not a single fixed dose or formulation, and glycan testing offers an objective means of assessing whether adjustments to estradiol, progesterone, or testosterone are producing the expected biological effect.

"There's no single biomarker that can function for everything, but glycans are predictive, they're responsive, they're stable. They are such a great indicator of inflammation and a very, very good biomarker of aging."

— Dr. Joseph Raffaele, MD, Founder, Raffaele Medical

How should clinicians use GlycanAge in an HRT protocol practically?

The recommended clinical workflow begins with a GlycanAge baseline before initiating HRT, establishing the patient's inflammatory starting point and enabling meaningful comparison at retest. If GlycanAge is elevated relative to chronological age in a woman aged 40–55 with cycle irregularity, vasomotor symptoms, or hormonal disruption, perimenopause or menopause should be considered as a driver even in the absence of classic presentation. The GlycanAge HRT Prescribing Algorithm, developed for professional use, guides clinicians through formulation decisions: transdermal 17β-estradiol is preferred over oral where possible to avoid elevated VTE risk; micronized progesterone is indicated where a uterus is present; testosterone is considered for low libido, energy, and focus, ensuring the patient is well-estrogenized first. Retesting at six months allows the clinician to assess whether the regimen has produced a measurable shift in biological age and glycan profile, and to adjust accordingly, though timing may vary depending on the starting regimen and the patient's individual rate of response. GlycanAge is not a diagnostic tool, but a biomarker for monitoring and intervention validation, to be interpreted alongside clinical history, hormone levels, and symptom assessment.

Does HRT also reduce long-term disease risk, and can GlycanAge track that?

HRT's impact extends well beyond symptom control: at the molecular level, it helps stabilize IgG glycosylation in ways that may contribute to lower long-term risk of cardiovascular, metabolic, and autoimmune conditions. Evidence, particularly from studies using body-identical hormones, supports reductions in cardiovascular disease, osteoporosis, type 2 diabetes risk, and potentially dementia. The pro-inflammatory changes that accompany estrogen decline, long assumed to be an inevitable feature of aging, are measurably reversible with well-managed HRT. GlycanAge captures this systemic benefit objectively: because it measures the inflammatory biology underlying these conditions rather than individual disease markers, it provides an integrated signal of long-term health trajectory that standard blood panels cannot. The standard GlycanAge provider report includes cardiovascular glycan insights, covering associations with atherosclerosis, coronary artery disease, and MI/CVA risk, allowing clinicians to assess whether HRT is producing the expected cardiovascular benefit alongside the broader biological age shift.

What should practitioners tell patients before they see their GlycanAge result?

Patients should be prepared for the possibility that their biological age may differ significantly from their chronological age in either direction. Results may come in substantially better than expected, or substantially higher, and in both cases, the more important clinical conversation is always about the trajectory of change rather than the initial number. Framing the result as a baseline (the starting point for a monitored intervention) rather than a verdict reduces the emotional charge and focuses the clinical conversation on what can be done.

"Having another biological test is really important — because so many women are not listened to, not believed about their symptoms."

— Dr. Louise Newson, menopause specialist and founder of Newson Health

Clinicians should also communicate that meaningful biological age reductions are achievable: the average reduction across repeat testers is 6 years, and women on optimized HRT protocols frequently see reductions well beyond that.

Practitioners integrating GlycanAge into HRT and menopause care can access the full clinical protocol, the HRT Prescribing Algorithm, and the Provider Report, including the Biological Age Rank metric, through the GlycanAge Healthcare Providers page. The protocol is designed to support baseline assessment, HRT titration, and retest interpretation within a standard clinical workflow.

Ready to add objective biological age monitoring to your HRT protocols? Visit the GlycanAge Healthcare Providers page to access clinical resources, order provider test kits, and register for upcoming clinical training on hormonal changes in perimenopause and immune aging.

External sources

• https://academic.oup.com/biomedgerontology/article/69/7/779/662651 — Krištić J, Vučković F, Menni C, Klarić L, Keser T, Beceheli I, et al. Glycans Are a Novel Biomarker of Chronological and Biological Ages. The Journals of Gerontology: Series A. 2014;69(7):779–89.

• https://www.aging-us.com/article/104060/text — Jurić J, Kohrt WM, Kifer D, Gavin KM, Pezer M, Nigrovic PA, Lauc G. Effects of estradiol on biological age measured using the glycan age index. Aging (Albany NY). 2020 Oct 13;12(19):19756–19765.

• https://insight.jci.org/articles/view/89703 — Ercan A, Kohrt WM, Cui J, Deane KD, Pezer M, Yu EW, Hausmann JS, Campbell H, Kaiser UB, Rudd PM, Lauc G. Estrogens regulate glycosylation of IgG in women and men. JCI Insight. 2017 Feb 23;2(4):e89703.

• https://www.newsonhealth.co.uk/ — Newson Health — menopause clinical resources.